Vaishnavi Chintala

Vaishnavi Chintala

Auto-generated profile, based on publicly available information

Vaishnavi Chintala

Cambrex High Point High Point North Carolina USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in Journal of Separation Science
Verified
Journal Article
Closed access
SLSanthi Priya Lankalapalli
Santhi Priya Lankalapalli
KRK. Vijaya Rachel
K. Vijaya Rachel
VCVaishnavi Chintala
Vaishnavi Chintala
LKLeela Prasad Kowtharapu
Leela Prasad Kowtharapu
NKNaresh Kumar Katari
Naresh Kumar Katari


27 September 2023 in Journal of AOAC INTERNATIONAL
Verified
Journal Article
Closed access
PDF file
SCSrinivasa Reddy Chinta
Srinivasa Reddy Chinta
VCVaishnavi Chintala
Vaishnavi Chintala
VNVishnu Nandimalla
Vishnu Nandimalla
RCRajyalakshmi Ch
Rajyalakshmi Ch
SESasikiran Goud Ediga
Sasikiran Goud Ediga
NKNaresh Kumar Katari
Naresh Kumar Katari
Background: The estimation of drugs containing drospirenone (DRSP) and ethinyl estradiol (EE), and their related impurities, in low-dose oral contraceptive drug products is an extremely challenging target. The proposed research sought to develop and validate a stability-indicating method for quantifying drug substances and their related impurities in tablet formulation. Objective: To develop and validate a simple, specific, accurate, precise, and stability-indicating reverse-phase (RP)-HPLC method for quantification of DRSP, EE, and their impurities in accordance with International Conference on Harmonisation (ICH) guidelines. Method: The separation was achieved using an Agilent Zorbax SB C18 column (4.6 mm × 250 mm, 5 µm) with a detection wavelength of 215 nm and mobile phases A (100% acetonitrile) and B (acetonitrile–water, 1 + 3, v/v) at a flow rate of 1.3 mL/min and a column temperature of 40°C. Results: The recovery study of each impurity was conducted in the range of 24 to 72 µg/mL for DRSP-related impurities and 0.2 to 0.6 µg/mL for EE-related impurities with respect to the specification limit. A linearity study was conducted over a range of 1.5 to 90 µg/mL for DRSP and DRSP-related impurities, and 0.125 to 0.75 µg/mL for EE-related impurities. A Quality by Design (QbD) study demonstrated the method’s robustness. Conclusions: As per current guidelines, a stability-indicating method has been developed for the determination of impurities in DRSP/EE film-coated tablets. A QbD-based robustness test was performed and the method was found to be robust. Highlights: An accurate, precise, stability-indicating, gradient RP-HPLC method has been developed and validated to determine DRSP, EE, and nine related impurities in tablet formulation. A QbD technique was used to establish a robustness study.